Clinical Trial: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight, With or Without Type 2 Diabetes Mellitus (EMBOLD) (China)

China, Nov. 2 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight, With or Without Type 2 Diabetes Mellitus (EMBOLD)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135627

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: Liaoyou Gem Flower Hospital of Panjin

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=350205

Published by HT Digital Content Services with permission from Health Daily Digest....